These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28554602)

  • 1. The relationship between diversion-related attitudes and sharing and selling buprenorphine.
    Kenney SR; Anderson BJ; Bailey GL; Stein MD
    J Subst Abuse Treat; 2017 Jul; 78():43-47. PubMed ID: 28554602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
    Johnson B; Richert T
    J Subst Abuse Treat; 2015 Jul; 54():50-5. PubMed ID: 25744650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.
    Johnson B; Richert T
    J Addict Dis; 2015; 34(1):1-17. PubMed ID: 25496247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
    Johnson B; Richert T
    Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients.
    Launonen E; Alho H; Kotovirta E; Wallace I; Simojoki K
    Int J Drug Policy; 2015 Sep; 26(9):875-82. PubMed ID: 25934054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.
    Allen B; Harocopos A
    J Subst Abuse Treat; 2016 Nov; 70():81-86. PubMed ID: 27692193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
    Johnson B; Richert T
    J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
    Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
    J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revising our attitudes towards agonist medications and their diversion in a time of pandemic.
    Del Pozo B; Rich JD
    J Subst Abuse Treat; 2020 Dec; 119():108139. PubMed ID: 33138924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "I'm Not a Good Drug Dealer": Styles of Buprenorphine Diversion in a Multisite Qualitative Study.
    McLean K; Kavanaugh PR
    Subst Use Misuse; 2022; 57(3):452-460. PubMed ID: 35067160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinician beliefs and attitudes about buprenorphine/naloxone diversion.
    Schuman-Olivier Z; Connery H; Griffin ML; Wyatt SA; Wartenberg AA; Borodovsky J; Renner JA; Weiss RD
    Am J Addict; 2013; 22(6):574-80. PubMed ID: 24131165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis.
    Zheng W; Nickasch M; Lander L; Wen S; Xiao M; Marshalek P; Dix E; Sullivan C
    J Addict Med; 2017; 11(2):138-144. PubMed ID: 28107210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.
    Cushman PA; Liebschutz JM; Anderson BJ; Moreau MR; Stein MD
    J Subst Abuse Treat; 2016 Sep; 68():68-73. PubMed ID: 27431049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
    Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
    J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
    Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'.
    Havnes IA; Clausen T; Middelthon AL
    Harm Reduct J; 2013 Oct; 10():24. PubMed ID: 24131626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder.
    Feder KA; Krawczyk N; Saloner B
    J Adolesc Health; 2017 Jun; 60(6):747-750. PubMed ID: 28258807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions and practices addressing diversion among US buprenorphine prescribers.
    Lin LA; Lofwall MR; Walsh SL; Gordon AJ; Knudsen HK
    Drug Alcohol Depend; 2018 May; 186():147-153. PubMed ID: 29573649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.